EGFR and non-small cell lung carcinoma: In a phase Ib study of atezolizumab in combination with erlotinib in treatment-naïve epidermal growth factor receptor (EGFR) mutation-positive advanced NSCLC, the ORR was 75% and median PFS was 15 months.